Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac
Autor(a) principal: | |
---|---|
Data de Publicação: | 2002 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/143530 |
Resumo: | This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional nonsteroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses of celecoxib 200 mg once daily or 200 mg twice daily, or diclofenac 75 mg twice daily for 5 days in a double-blind, randomized study. The primary efficacy assessment was ‘Throat Pain on Swallowing’ on day 3. In addition, secondary quality-of-life assessments were performed on days 3 and 5. All adverse events and treatment-emergent signs and symptoms were recorded. Data from 313 patients were evaluable for efficacy (105 celecoxib 200 mg once daily, 107 celecoxib 200 mg twice daily, 101 diclofenac 75 mg twice daily). The upper 95% confidence limits for the visual analog scale of ‘Throat Pain on Swallowing’ on day 3 for celecoxib 200 mg once daily relative to diclofenac 75 mg twice daily, and celecoxib 200 mg twice daily relative to diclofenac 75 mg twice daily were 9.26 and 7.83, respectively. All secondary efficacy and quality-of-life measures were clinically similar for the three treatment groups, and no statistically significant differences were detected The incidences of treatmentemergent adverse events and withdrawals due to adverse events were similar for all groups, but numerically higher among patients taking diclofenac than celecoxib. More patients in the diclofenac group reported gastrointestinal complaints (7.3%) compared with those in the celecoxib groups (4.3% in the celecoxib 200 mg once-daily group and 3.4% in the celecoxib 200 mg twice-daily group). In conclusion, 5 days of treatment with celecoxib 200 mg once daily is as effective as diclofenac 75 mg twice daily in the symptomatic treatment of viral pharyngitis. Celecoxib 200 mg once daily is also as effective as celecoxib 200 mg twice daily in this condition. |
id |
UFRGS-2_6c0c7f0090399c87ef10c158576ca068 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/143530 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Weckx, Luc Louis MauriceRuiz, Jorge EliecerDuperly, J.Martínez Mendizabal, G. A.Rausis, M. B. G.Piltcher, Simao LevinSaffer, MoacyrMatsuyama, C.Levy, S.Fort, J. G.2016-07-13T02:33:38Z20021473-2300http://hdl.handle.net/10183/143530000390052This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional nonsteroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses of celecoxib 200 mg once daily or 200 mg twice daily, or diclofenac 75 mg twice daily for 5 days in a double-blind, randomized study. The primary efficacy assessment was ‘Throat Pain on Swallowing’ on day 3. In addition, secondary quality-of-life assessments were performed on days 3 and 5. All adverse events and treatment-emergent signs and symptoms were recorded. Data from 313 patients were evaluable for efficacy (105 celecoxib 200 mg once daily, 107 celecoxib 200 mg twice daily, 101 diclofenac 75 mg twice daily). The upper 95% confidence limits for the visual analog scale of ‘Throat Pain on Swallowing’ on day 3 for celecoxib 200 mg once daily relative to diclofenac 75 mg twice daily, and celecoxib 200 mg twice daily relative to diclofenac 75 mg twice daily were 9.26 and 7.83, respectively. All secondary efficacy and quality-of-life measures were clinically similar for the three treatment groups, and no statistically significant differences were detected The incidences of treatmentemergent adverse events and withdrawals due to adverse events were similar for all groups, but numerically higher among patients taking diclofenac than celecoxib. More patients in the diclofenac group reported gastrointestinal complaints (7.3%) compared with those in the celecoxib groups (4.3% in the celecoxib 200 mg once-daily group and 3.4% in the celecoxib 200 mg twice-daily group). In conclusion, 5 days of treatment with celecoxib 200 mg once daily is as effective as diclofenac 75 mg twice daily in the symptomatic treatment of viral pharyngitis. Celecoxib 200 mg once daily is also as effective as celecoxib 200 mg twice daily in this condition.application/pdfengJournal of international medical research. Northampton. Vol. 30, no. 2 (Mar./Apr. 2002), p. 185-194FaringiteAerofagiaTratamento farmacológicoCelecoxibCyclooxygenase (COX)-2 specific inhibitorsViral pharyngitisSymptomatic treatmentThroat pain on swallowingEfficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenacEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000390052.pdf000390052.pdfTexto completo (inglês)application/pdf45823http://www.lume.ufrgs.br/bitstream/10183/143530/1/000390052.pdfc8bbaff75fab1ad746907a9cb010eadeMD51TEXT000390052.pdf.txt000390052.pdf.txtExtracted Texttext/plain30250http://www.lume.ufrgs.br/bitstream/10183/143530/2/000390052.pdf.txt8f64a5ae55a905f20609b7134cc37f78MD52THUMBNAIL000390052.pdf.jpg000390052.pdf.jpgGenerated Thumbnailimage/jpeg2227http://www.lume.ufrgs.br/bitstream/10183/143530/3/000390052.pdf.jpgf6b14dc5b5a3e0d136bf562bd5b83b82MD5310183/1435302023-08-18 03:41:53.288018oai:www.lume.ufrgs.br:10183/143530Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2023-08-18T06:41:53Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
title |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
spellingShingle |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac Weckx, Luc Louis Maurice Faringite Aerofagia Tratamento farmacológico Celecoxib Cyclooxygenase (COX)-2 specific inhibitors Viral pharyngitis Symptomatic treatment Throat pain on swallowing |
title_short |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
title_full |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
title_fullStr |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
title_full_unstemmed |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
title_sort |
Efficaccy of celecoxib in treating symptoms of viral pharyngitis : a double-blind, randomized study of celecoxib versus diclofenac |
author |
Weckx, Luc Louis Maurice |
author_facet |
Weckx, Luc Louis Maurice Ruiz, Jorge Eliecer Duperly, J. Martínez Mendizabal, G. A. Rausis, M. B. G. Piltcher, Simao Levin Saffer, Moacyr Matsuyama, C. Levy, S. Fort, J. G. |
author_role |
author |
author2 |
Ruiz, Jorge Eliecer Duperly, J. Martínez Mendizabal, G. A. Rausis, M. B. G. Piltcher, Simao Levin Saffer, Moacyr Matsuyama, C. Levy, S. Fort, J. G. |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Weckx, Luc Louis Maurice Ruiz, Jorge Eliecer Duperly, J. Martínez Mendizabal, G. A. Rausis, M. B. G. Piltcher, Simao Levin Saffer, Moacyr Matsuyama, C. Levy, S. Fort, J. G. |
dc.subject.por.fl_str_mv |
Faringite Aerofagia Tratamento farmacológico |
topic |
Faringite Aerofagia Tratamento farmacológico Celecoxib Cyclooxygenase (COX)-2 specific inhibitors Viral pharyngitis Symptomatic treatment Throat pain on swallowing |
dc.subject.eng.fl_str_mv |
Celecoxib Cyclooxygenase (COX)-2 specific inhibitors Viral pharyngitis Symptomatic treatment Throat pain on swallowing |
description |
This study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional nonsteroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses of celecoxib 200 mg once daily or 200 mg twice daily, or diclofenac 75 mg twice daily for 5 days in a double-blind, randomized study. The primary efficacy assessment was ‘Throat Pain on Swallowing’ on day 3. In addition, secondary quality-of-life assessments were performed on days 3 and 5. All adverse events and treatment-emergent signs and symptoms were recorded. Data from 313 patients were evaluable for efficacy (105 celecoxib 200 mg once daily, 107 celecoxib 200 mg twice daily, 101 diclofenac 75 mg twice daily). The upper 95% confidence limits for the visual analog scale of ‘Throat Pain on Swallowing’ on day 3 for celecoxib 200 mg once daily relative to diclofenac 75 mg twice daily, and celecoxib 200 mg twice daily relative to diclofenac 75 mg twice daily were 9.26 and 7.83, respectively. All secondary efficacy and quality-of-life measures were clinically similar for the three treatment groups, and no statistically significant differences were detected The incidences of treatmentemergent adverse events and withdrawals due to adverse events were similar for all groups, but numerically higher among patients taking diclofenac than celecoxib. More patients in the diclofenac group reported gastrointestinal complaints (7.3%) compared with those in the celecoxib groups (4.3% in the celecoxib 200 mg once-daily group and 3.4% in the celecoxib 200 mg twice-daily group). In conclusion, 5 days of treatment with celecoxib 200 mg once daily is as effective as diclofenac 75 mg twice daily in the symptomatic treatment of viral pharyngitis. Celecoxib 200 mg once daily is also as effective as celecoxib 200 mg twice daily in this condition. |
publishDate |
2002 |
dc.date.issued.fl_str_mv |
2002 |
dc.date.accessioned.fl_str_mv |
2016-07-13T02:33:38Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/143530 |
dc.identifier.issn.pt_BR.fl_str_mv |
1473-2300 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000390052 |
identifier_str_mv |
1473-2300 000390052 |
url |
http://hdl.handle.net/10183/143530 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Journal of international medical research. Northampton. Vol. 30, no. 2 (Mar./Apr. 2002), p. 185-194 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/143530/1/000390052.pdf http://www.lume.ufrgs.br/bitstream/10183/143530/2/000390052.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/143530/3/000390052.pdf.jpg |
bitstream.checksum.fl_str_mv |
c8bbaff75fab1ad746907a9cb010eade 8f64a5ae55a905f20609b7134cc37f78 f6b14dc5b5a3e0d136bf562bd5b83b82 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
lume@ufrgs.br |
_version_ |
1817724985816383488 |